ERAS reported encouraging Phase 1 data from AURORAS-1 showing 57% unconfirmed ORR at eight weeks in KRAS G12X pancreatic cancer at 32 mg, with most responses ongoing. The company also upsized its public offering to raise about $550 million to support R&D and late-stage trials. Pipeline milestones include registration-enabling NSCLC in 1H 2027 and Phase 3 PDAC in 2027, potentially creating substantial value if executed.
Erasca, Inc. (NASDAQ: ERAS) is facing a severe decline after receiving allegations from Revolution Medicines regarding patent infringement related to its drug ERAS-0015. This news comes alongside the company’s announcement of preliminary Phase 1 results, raising concerns about the legal and commercial viability of its product.
Erasca's stock fell over 35% following the disclosure of a patient death in an early-stage cancer drug trial. Despite analysts indicating this incident is unlikely to point to larger safety concerns, the market reaction suggests heightened investor anxiety and potential volatility ahead.
Erasca Inc.'s stock fell 7.13%, influenced by Merck's aborted discussions with Revolution Medicines. Although Erasca continues its Phase 1 trials, investor sentiment may be concerned about market dynamics in oncology acquisitions. The recent $225 million funding supports its R&D pipeline but could face pressure from market fluctuations.
Erasca shares jumped 60% to $6.12 before falling to $4.33. The price movement stemmed from rumors of AbbVie acquiring Revolution Medicines. Revolution Medicines focuses on RAS-targeted therapies, impacting Erasca's field. Erasca is conducting Phase 1 trials for RAS-mutant solid tumors. Initial data of Erasca's lead drug ERAS-0015 is expected in 2026.
